Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




Hamburg, Germany - 10 November 2009: Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX) a leading provider in the discovery and
development of novel small molecule drugs today announced that it
plans to voluntarily delist its American Depositary Shares from the
NASDAQ stock market and concentrate its share trading on the recently
re-entered TecDAX platform.

Dr Werner Lanthaler, Chief Executive Officer of Evotec stated:
"Evotec follows the trading behaviour of its shareholders thereby
reducing unnecessary complexity in the capital market presence and
related costs. Despite this delisting we intend to continually
improve the information and service quality for our global
shareholder base."

Evotec has given formal notice to the NASDAQ of its intention to
voluntarily delist its American Depositary Shares. Evotec intends to
file a Form 25 with the NASDAQ on 20 November 2009 to initiate the
delisting which will become effective on 30 November 2009. As soon
thereafter as the Company is eligible, the Company intends to file a
Form 15 with the Securities and Exchange Commission to terminate the
registration of the American Depositary Shares and the underlying
ordinary shares.

During the second quarter of 2008 Evotec acquired Renovis and, in the
context of this transaction, listed on NASDAQ. The Evotec ADSs are
listed on the NASDAQ Global Market under the trading symbol "EVTC".
Based on the "Evotec 2012 - Action Plan to Focus and Grow" Evotec
implemented strict restructuring measures during the course of the
second quarter 2009. As a consequence of these measures, Evotec
closed its US operations in South San Francisco, California, during
the third quarter 2009.

Contact: Dr Werner Lanthaler, Chief Executive Officer,
Evotec AG, Tel.: +49.(0)40.56081-242,  werner.lanthaler@evotec.com

Forward-Looking Statements
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. Such
forward-looking statements include, but are not limited to,
statements about our expectations and assumptions concerning
regulatory, clinical and business strategies, the progress of our
clinical development programs and timing of the results of our
clinical trials, strategic collaborations and management's plans,
objectives and strategies. These statements are neither promises nor
guarantees, but are subject to a variety of risks and uncertainties,
many of which are beyond our control, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. In particular, the risks and
uncertainties include, among other things: risks that the Company may
be unable to reduce its cash burn through recent restructuring and
cost containment measures and may not recognize the results of such
measures within the expected timeframe; risks that product candidates
may fail in the clinic or may not be successfully marketed or
manufactured; the risk that we will not achieve the anticipated
benefits of our collaborations, partnerships and acquisitions in the
timeframes expected, or at all; risks relating to our ability to
advance the development of product candidates currently in the
pipeline or in clinical trials; our inability to further identify,
develop and achieve commercial success for new products and
technologies; the risk that competing products may be more
successful; our inability to interest potential partners in our
technologies and products; our inability to achieve commercial
success for our products and technologies; our inability to protect
our intellectual property and the cost of enforcing or defending our
intellectual property rights; our failure to comply with regulations
relating to our products and product candidates, including FDA
requirements; the risk that the FDA may interpret the results of our
studies differently than we have; the risk that clinical trials may
not result in marketable products; the risk that we may be unable to
successfully secure regulatory approval of and market our drug
candidates; and risks of new, changing and competitive technologies
and regulations in the U.S. and internationally.
The list of risks above is not exhaustive. Our most recent Annual
Report on Form 20-F, filed with the Securities and Exchange
Commission, and other documents filed with, or furnished to the
Securities and Exchange Commission, contain additional factors that
could impact our businesses and financial performance. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances
on which any such statement is based.

hugin.info/131215/R/1353706/327931.pdf


 
--- End of Message ---

Evotec AG
Schnackenburgallee 114 Hamburg Germany

WKN: 566480; ISIN: 
DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All 
Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Düsseldorf, 
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt 
in Frankfurter Wertpapierbörse;